Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4904229 | 0.84 | SLC6A1 (0.41) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL4908632 | 0.84 | SLC6A1 (0.41) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL4361686 | 0.84 | SLC6A1 (0.41) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| Tert-Butyl Formate SCHEMBL28013971 | 0.83 | TDP1 (0.41) | — | |
| SCHEMBL28863484 | 0.81 | SCN9A (0.43) | LMNATSHR | |
| SCHEMBL3444600 | 0.81 | SCN9A (0.43) | LMNATSHR | |
| SCHEMBL28241589 | 0.81 | SCN9A (0.43) | LMNATSHR | |
| SCHEMBL903961 | 0.78 | KDM4E (0.34) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL671201 | 0.78 | TDP1 (0.40) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL30605523 | 0.78 | USP2 (0.44) | KDM4EUSP2ALDH1A1LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023071998-A1 | NOVEL PYRIDO OR TRIAZINE-SUBSTITUTED PYRIDO HETEROCYCLIC COMPOUND | 杭州德睿智药科技有限公司 | 2023-05-04 | — | — | WO | disclosed |
| WO-2018108954-A1 | PROCESS FOR THE PREPARATION OF 2-(3-(FLUOROMETHYL)AZETIDIN-1-YL)ETHAN-1-OL | F. HOFFMANN-LA ROCHE AG (CH) | 2018-06-21 | — | — | WO | disclosed |
| EP-3066090-A1 | 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | iTeos Therapeutics (BE) | 2016-09-14 | — | — | EP | disclosed |
| EP-3010501-A1 | ESTROGEN RECEPTOR MODULATOR AND USES THEREOF | Seragon Pharmaceuticals, Inc. (US) | 2016-04-27 | — | — | EP | disclosed |
| WO-2015067782-A1 | 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-05-14 | — | — | WO | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| WO-2014205138-A1 | ESTROGEN RECEPTOR MODULATOR AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. (US) | 2014-12-24 | — | — | WO | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| EP-2616465-A1 | TRIAZINE-OXADIAZOLES | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| EP-2058302-B1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2013-04-17 | — | — | EP | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | KDM4E 3067/4885USP2 3711/4885ALDH1A1 439/4885 |
| US-20140051676-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | KDM4E 3067/4885USP2 3711/4885ALDH1A1 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.